X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (42012) 42012
Book Review (8912) 8912
Newspaper Article (2172) 2172
Publication (1782) 1782
Newsletter (1747) 1747
Magazine Article (309) 309
Conference Proceeding (272) 272
Book Chapter (165) 165
Trade Publication Article (135) 135
Web Resource (50) 50
Book / eBook (33) 33
Transcript (33) 33
Dissertation (12) 12
Reference (5) 5
Government Document (4) 4
Data Set (3) 3
Paper (3) 3
Presentation (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (33889) 33889
humans (33325) 33325
anticoagulants (20677) 20677
male (16592) 16592
female (16282) 16282
anticoagulants - administration & dosage (15814) 15814
anticoagulants - therapeutic use (13061) 13061
middle aged (11126) 11126
aged (10989) 10989
anticoagulants - adverse effects (8709) 8709
adult (7591) 7591
warfarin (7270) 7270
risk factors (7009) 7009
treatment outcome (6232) 6232
abridged index medicus (6057) 6057
administration, oral (5992) 5992
hematology (5829) 5829
cardiac & cardiovascular systems (5466) 5466
peripheral vascular disease (5432) 5432
thrombosis (5279) 5279
stroke (4631) 4631
thromboembolism (4553) 4553
aged, 80 and over (4511) 4511
surgery (4466) 4466
animals (4395) 4395
heparin (4307) 4307
prevention (4232) 4232
atrial fibrillation (4212) 4212
warfarin - administration & dosage (3985) 3985
drug therapy (3843) 3843
care and treatment (3796) 3796
pharmacology & pharmacy (3664) 3664
heparin - administration & dosage (3656) 3656
anticoagulation (3632) 3632
hemorrhage - chemically induced (3498) 3498
retrospective studies (3494) 3494
therapy (3461) 3461
medicine, general & internal (3417) 3417
time factors (3413) 3413
dosage and administration (3369) 3369
venous thromboembolism (3327) 3327
analysis (3247) 3247
research (3128) 3128
anticoagulants - pharmacology (3124) 3124
risk (3113) 3113
management (3018) 3018
atrial fibrillation - drug therapy (2975) 2975
patients (2792) 2792
warfarin - therapeutic use (2770) 2770
international normalized ratio (2710) 2710
medicine & public health (2703) 2703
heparin - therapeutic use (2691) 2691
health aspects (2681) 2681
molecular-weight heparin (2670) 2670
dabigatran (2626) 2626
prospective studies (2624) 2624
mortality (2551) 2551
dose-response relationship, drug (2450) 2450
thromboembolism - prevention & control (2435) 2435
warfarin - adverse effects (2433) 2433
rivaroxaban (2405) 2405
stroke - prevention & control (2362) 2362
blood coagulation - drug effects (2359) 2359
cardiology (2184) 2184
glycosaminoglycans (2178) 2178
aspirin (2160) 2160
hemorrhage (2122) 2122
risk assessment (2122) 2122
atrial fibrillation - complications (2100) 2100
follow-up studies (2099) 2099
thrombin (2090) 2090
heparin - adverse effects (2063) 2063
atrial-fibrillation (1978) 1978
deep-vein thrombosis (1912) 1912
adolescent (1856) 1856
cardiac arrhythmia (1846) 1846
medical research (1832) 1832
clinical trials (1813) 1813
drug administration schedule (1808) 1808
coagulation (1772) 1772
complications and side effects (1742) 1742
bleeding (1734) 1734
anticoagulant (1679) 1679
platelet aggregation inhibitors - therapeutic use (1674) 1674
drug therapy, combination (1664) 1664
thrombosis - prevention & control (1650) 1650
pregnancy (1633) 1633
safety (1628) 1628
usage (1625) 1625
complications (1602) 1602
fibrinolytic agents - therapeutic use (1582) 1582
internal medicine (1561) 1561
unfractionated heparin (1553) 1553
venous thrombosis - drug therapy (1520) 1520
anticoagulants - pharmacokinetics (1513) 1513
venous thrombosis (1503) 1503
enoxaparin (1501) 1501
heparin, low-molecular-weight - therapeutic use (1493) 1493
stroke - etiology (1473) 1473
pulmonary embolism (1468) 1468
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (16) 16
Online Resources - Online (11) 11
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gerstein Science - May be requested in 6-10 wks (1) 1
Scarborough Hospital - Hospital Department (1) 1
West Park Healthcare Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (42798) 42798
German (1066) 1066
French (680) 680
Russian (376) 376
Spanish (358) 358
Japanese (314) 314
Italian (184) 184
Polish (92) 92
Hungarian (91) 91
Chinese (86) 86
Swedish (81) 81
Danish (74) 74
Norwegian (62) 62
Dutch (59) 59
Czech (52) 52
Portuguese (44) 44
Turkish (34) 34
Finnish (15) 15
Ukrainian (15) 15
Bulgarian (14) 14
Romanian (14) 14
Hebrew (13) 13
Serbian (12) 12
Lithuanian (11) 11
Croatian (10) 10
Korean (10) 10
Icelandic (3) 3
Persian (2) 2
Slovak (2) 2
Bosnian (1) 1
Georgian (1) 1
Slovenian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Circulation (Baltimore), ISSN 0009-7322, 12/2010, Volume 122, Issue 25, pp. 2709 - 2717
Journal Article
The Lancet, ISSN 0140-6736, 08/2001, Volume 358, Issue 9282, pp. 605 - 613
Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa... 
MEDICINE, GENERAL & INTERNAL | THROMBOLYSIS | Recurrence | Humans | Middle Aged | Heparin - administration & dosage | Male | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Chi-Square Distribution | Enoxaparin - administration & dosage | Immunoglobulin Fab Fragments - administration & dosage | Injections | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Survival Analysis | Female | Aged | Fibrinolytic Agents - administration & dosage | Drug Therapy, Combination | Dosage and administration | Thrombolytic drugs | Research | Tenecteplase | Drug therapy | Heart attack | Prevention | Evaluation | Ischemia | Enoxaparin | Reperfusion (Physiology) | Drug therapy, Combination | Heparin | Health aspects | Clinical trials | Heart attacks | Myocardial infarction | Coagulation | Hemorrhage | Bleeding | Infusion | Randomization | Reperfusion | Motivation | Blood platelets | Safety | Heparins | Anticoagulants | Stroke | Effectiveness | Complications | Mortality | Glycoprotein | Pharmacology | Patients | Trauma | Molecular chains | Studies | Fibrin | Monoclonal antibodies | Infarction | Index Medicus | Abridged Index Medicus | Heparin/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Platelet Aggregation Inhibitors/administration & dosage | MEDICINE | Antibodies; Monoclonal/administration & dosage | Myocardial Infarction/drug therapy | Enoxaparin/administration & dosage | Tissue Plasminogen Activator/administration & dosage | Fibrinolytic Agents/administration & dosage | MEDICIN | Immunoglobulins; Fab/administration & dosage | Drug Therapy; Combination | Research Support; Non-U.S. Gov't
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
AimsThe anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
cytochrome | glycoprotein | rivaroxaban | drug interactions | healthy subjects | 450 | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | cytochrome P450 | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism | Index Medicus
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 06/2016, Volume 5, Issue 6, p. n/a
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2014, Volume 12, Issue 9, pp. 1428 - 1436
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 1, pp. 9 - 19
In patients with acute coronary syndromes, low doses of rivaroxaban were effective in reducing the primary end point of death from cardiovascular causes,... 
ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | PLACEBO | EVENTS | MYOCARDIAL-INFARCTION | SAFETY | DOUBLE-BLIND | THROMBOPROPHYLAXIS | APIXABAN | FACTOR XA INHIBITOR | ANTIPLATELET THERAPY | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hemorrhage - mortality | Male | Secondary Prevention | Thiophenes - administration & dosage | Incidence | Rivaroxaban | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Morpholines - administration & dosage | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acute Coronary Syndrome - drug therapy | Intracranial Hemorrhages - chemically induced | Aged | Hemorrhage - chemically induced | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Coronary heart disease | Myocardial infarction | Cerebral infarction | Anticoagulants | Heart attacks | Arteriosclerosis | Cardiovascular disease | Death | Angina pectoris | Hemorrhage | Thrombosis | Bleeding | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article